It wasn’t a subject Deepak Ghaisas understood at all. But he was trying, even before he fully exited i-flex, a financial product company that he had incubated at Citi Group, which was acquired by Oracle in 2005. When Ghaisas did exit, in 2008, he was convinced he wanted to do something “different at age 50”. A year later, that something turned out to be stem cells. As someone who would attend seminars and text his biologist wife to understand the difference between ‘in vitro’ (in a lab) ‘in vivo’ (in an organism), Ghaisas’ foray into stem cells, a class of cells that can repair organs and promise to cure some diseases, was rather unusual.